血肿扩大移位分析评估急性脑出血治疗
本研究基于ATACH-2试验数据,提出血肿扩大移位分析模型,用于评估急性脑出血候选疗法。分析863例患者发现,强化降压治疗在血肿扩大最高分层中显示血肿增长减少,提示该模型可提供额外生物学效应信息。
要点
- 血肿扩大移位分析可评估脑出血治疗效应
- 强化降压或优先减缓高血肿扩大风险患者增长
- 该模型可能为未来止血药研究提供额外评估方式
核心结论
- 强化降压可能优先减缓高血肿扩大风险患者的血肿增长。
- 血肿扩大移位分析可提供治疗生物学效应的额外信息。
研究设计与样本
- 基于ATACH-2试验数据的概念验证研究,主要分析人群863例。
- 采用多分类分层、百分位/绝对四分位及24小时血肿体积四分位进行移位分析。
- 使用比例优势模型探讨降压治疗与血肿扩大移位的关系。
主要发现
- 两种治疗组中约三分之一患者无血肿扩大。
- 三分类最高分层≥33%显示强化治疗组血肿增长减少5.8%(aOR 0.77,95%CI 0.60-0.99)。
- 血肿体积变化百分位四分位显示强化治疗组有利移位减少增长(aOR 0.73,95%CI 0.57-0.93)。
- 24小时血肿体积四分类分析中最高分层(>21.9 mL)移位最显著。
临床怎么用
- 血肿扩大移位分析可作为评估脑出血治疗效应的补充方法。
- 未来研究可用该模型评估止血药物的生物学效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hematoma expansion (HE) is commonly analyzed as a dichotomous outcome in intracerebral hemorrhage (ICH) trials. In this proof-of-concept study, we propose an HE shift analysis model as a method to improve the evaluation of candidate ICH therapies. METHODS: Using data from the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-2) trial, we performed HE shift analysis in response to intensive blood pressure lowering by generating polychotomous strata based on previously established HE definitions, percentile/absolute quartiles of hematoma volume change, and quartiles of 24-hour follow-up hematoma volumes. The relationship between blood pressure treatment and HE shift was explored with proportional odds models. RESULTS: The primary analysis population included 863 patients. In both treatment groups, approximately one-third of patients exhibited no HE. With the use of a trichotomous HE stratification, the highest strata of ≥33% revealed a 5.8% reduction in hematoma growth for those randomized to intensive therapy (adjusted odds ratio [aOR] 0.77, 95% confidence interval [CI] 0.60-0.99). Using percentile quartiles of hematoma volume change, we observed a favorable shift to reduce growth in patients treated with intensive therapy (aOR 0.73, 95% CI 0.57-0.93). Similarly, in a tetrachotomous analysis of 24-hour follow-up hematoma volumes, shifts in the highest stratum (>21.9 mL) were most notable. CONCLUSIONS: Our findings suggest that intensive blood pressure reduction may preferentially mitigate growth in patients at risk of high volume HE. A shift analysis model of HE provides additional insights into the biological effects of a given therapy and may be an additional way to assess hemostatic agents in future studies. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier:NCT01176565.
引用
- Yogendrakumar V, Ramsay T, Menon BK, et al. Hematoma Expansion Shift Analysis to Assess Acute Intracerebral Hemorrhage Treatments. Neurology. 2021. PMID: 34144995. doi:10.1212/WNL.0000000000012393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。